amfAR, The Foundation for AIDS Research

HIV and Hepatitis C

Averhoff FM, et al. Clinical Infectious Diseases, 2012; 55: S10–S15

About five million people living with HIV, or 15% of the total HIV-positive population, are co-infected with hepatitis C, and Southeast Asia and Africa have larger numbers of co-infected individuals than other regions. However, due to the prohibitively high cost of effective hepatitis C treatments and a lack of physician experience in managing the treatment and its side effects, many people with hepatitis C in Asia remain untreated. As a result, hepatitis C co-infection has become a significant cause of death among people living with HIV in the region.

TREAT Asia is investigating how to better diagnose and treat hepatitis C in individuals co-infected with HIV in resource-limited settings, with the aim of developing a pilot model for treatment provision and education that can be replicated across the Asia-Pacific. TREAT Asia is also collaborating with regional partners to advocate for the increased availability of hepatitis C treatment in Asia.

Featured Articles

How Activists Are Driving Down the Cost of Hepatitis C Treatment in Asia

How the WHO Is Taking the Lead in Combating Global Hepatitis

Treating Hepatitis C Among People Who Use Drugs

Fact Sheet: WHO Guidelines for the Screening, Care, and Treatment of Persons with Hepatitis C Infection

Educational Materials on Hepatitis C Co-infection

Policy Brief: Hepatitis C and HIV – Addressing the Dual Epidemic

WHO Releases First International Hepatitis C Treatment Guidelines

TREAT Asia Launches a New Hepatitis C Education Campaign and Screening and Treatment Study

Screening For Hepatitis Can Improve HIV Care

TREAT Asia Launches Hepatitis C Co-Infection Study